Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Triamcinolone Injection Clear all
Completed Phase 2 Interventional

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

NCT00231023
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Peribulbar Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

NCT05436535
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 3, 2026, 8:04 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis

NCT05526898
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
SyntrFuge System, Triamcinolone Injection
Device · Drug
Lead sponsor
Syntr Health Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

NCT01175395
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
IBI-20089/Lucentis
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 3, 2026, 8:04 PM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids

NCT04710719
View directory record Official record
Conditions
Keloid, Keloid Scar Following Surgery
Interventions
Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil injection
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Comparing the Effects of Ultrasound Versus Fluoroscopy for Sacroiliac Joint Injections

NCT02420041
View directory record Official record
Conditions
Sacroiliitis
Interventions
Active comparator: Fluoroscopic Guided SIJ injection, Ultrasound Guided Sacroiliac Joint Injection, Havel's Inc. EchoStim (facet tip) 21 Gauge 4" needle, SonoSite S-nerve, iohexol, triamcinolone/lidocaine
Procedure · Device · Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 3, 2026, 8:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.

NCT07151417
View directory record Official record
Conditions
Knee Osteoarthritis, Musculoskeletal Disease, Surgery
Interventions
PAI, PAI + steroid, PAI + zilretta
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone

NCT03641508
View directory record Official record
Conditions
Trigger Finger Disorder
Interventions
Triamcinolone, Dexamethasone
Drug
Lead sponsor
Ericka Lawler
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 3, 2026, 8:04 PM EDT
Recruiting Phase 4 Interventional

Knee Injections for Obese Patients With Knee Arthritis

NCT06782529
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Triamcinolone Acetonide Low Dose, Triamcinolone Acetonide Standard Dose
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 3, 2026, 8:04 PM EDT
Not listed Phase 4 Interventional

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT02022722
View directory record Official record
Conditions
Dyspareunia
Interventions
Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis

NCT03072381
View directory record Official record
Conditions
Chronic Lateral Epicondylosis
Interventions
Platelet Rich Plasma - Group 1, Corticosteroid Control - Group 2
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 3, 2026, 8:04 PM EDT
Withdrawn Phase 1 Interventional

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

NCT04655391
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate, Gilteritinib Fumarate, Glasdegib Maleate, Ivosidenib, Venetoclax
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Not applicable Interventional Results available

Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome

NCT01190891
View directory record Official record
Conditions
Shoulder Impingement Syndrome
Interventions
Manual Physical Therapy, Corticosteroid Injection
Procedure
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 3, 2026, 8:04 PM EDT
Terminated Phase 4 Interventional Results available

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

NCT03382925
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline
Procedure · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Sep 3, 2026, 8:04 PM EDT
Completed No phase listed Observational

Knee Steroid Injection and Blood Sugar Signatur

NCT04317404
View directory record Official record
Conditions
Diabetes, Knee Osteoarthritis
Interventions
40 mg Triamcinolone acetonide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT05811351
View directory record Official record
Conditions
Geographic Atrophy
Interventions
JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

NCT02949024
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT Aflibercept, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Mountain View, California • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 8:04 PM EDT
Terminated Phase 4 Interventional Results available

Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection

NCT03166761
View directory record Official record
Conditions
Sacro-Iliac Spondylosis
Interventions
Dexamethasone, Triamcinolone Acetonide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 4 Interventional Results available

Effect of Steroid Injections in a Knee With Osteoarthritis

NCT01230424
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 3, 2026, 8:04 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 3, 2026, 8:04 PM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 8:04 PM EDT